




## INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

<b>(51) International Patent Classification <sup>6</sup> :</b> <b>C07D 211/46, 207/12, 207/08, A61K 31/445, 31/40</b>	<b>A1</b>	<b>(11) International Publication Number:</b> <b>WO 99/37616</b> <b>(43) International Publication Date:</b> 29 July 1999 (29.07.99)
<b>(21) International Application Number:</b> PCT/GB99/00231 <b>(22) International Filing Date:</b> 22 January 1999 (22.01.99) <b>(30) Priority Data:</b> 9801398.0                      22 January 1998 (22.01.98)                      GB <b>(71)(72) Applicants and Inventors:</b> ÄNGGÅRD, Erik, Emil [SE/GB]; West Wing, Baldon House, Marsh Baldon, Oxford OX44 9LS (GB). HAJ-YEHIA, Abdullah, Ibrahim [-/IL]; P.O. Box 12065, 91120 Jerusalem (IL). <b>(74) Agent:</b> HOWARD, Paul, Nicholas; Carpmaels & Ransford, 43 Bloomsbury Square, London WC1A 2RA (GB).		<b>(81) Designated States:</b> AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW, ARIPO patent (GH, GM, KE, LS, MW, SD, SZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).  <b>Published</b> <i>With international search report.</i> <i>Before the expiration of the time limit for amending the claims and to be republished in the event of the receipt of amendments.</i>

**(54) Title:** PIPERIDINE AND PYRROLIDINE DERIVATIVES COMPRISING A NITRIC OXIDE DONOR FOR TREATING STRESS

**(57) Abstract**

The present invention relates to chemical compounds comprising a nitric oxide (NO) donor and a superoxide ion ( $O_2^-$ ) scavenger, their preparation and their use in the treatment of conditions associated with oxidative stress or endothelial dysfunction. In particular, the present invention relates to chemical compounds of formula (I) wherein:  $R^1$  may be the same or different and are independently selected from hydrogen, alkoyl, alkoxy, carboxy, hydroxy, amino, amido, cyano, nitro, thio, sulphonyl, sulphoxide alkyl groups comprising an NO-donor, provided that at least one  $R^1$  is a group comprising an NO-donor;  $R^2$  may be the same or different and are independently selected from alkyl groups; n is an integer 1, 2 or 3; or a salt thereof.

**FOR THE PURPOSES OF INFORMATION ONLY**

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AL	Albania	ES	Spain	LS	Lesotho	SI	Slovenia
AM	Armenia	FI	Finland	LT	Lithuania	SK	Slovakia
AT	Austria	FR	France	LU	Luxembourg	SN	Senegal
AU	Australia	GA	Gabon	LV	Latvia	SZ	Swaziland
AZ	Azerbaijan	GB	United Kingdom	MC	Monaco	TD	Chad
BA	Bosnia and Herzegovina	GE	Georgia	MD	Republic of Moldova	TG	Togo
BB	Barbados	GH	Ghana	MG	Madagascar	TJ	Tajikistan
BE	Belgium	GN	Guinea	MK	The former Yugoslav Republic of Macedonia	TM	Turkmenistan
BF	Burkina Faso	GR	Greece	ML	Mali	TR	Turkey
BG	Bulgaria	HU	Hungary	MN	Mongolia	TT	Trinidad and Tobago
BJ	Benin	IE	Ireland	MR	Mauritania	UA	Ukraine
BR	Brazil	IL	Israel	MW	Malawi	UG	Uganda
BY	Belarus	IS	Iceland	MX	Mexico	US	United States of America
CA	Canada	IT	Italy	NE	Niger	UZ	Uzbekistan
CF	Central African Republic	JP	Japan	NL	Netherlands	VN	Viet Nam
CG	Congo	KE	Kenya	NO	Norway	YU	Yugoslavia
CH	Switzerland	KG	Kyrgyzstan	NZ	New Zealand	ZW	Zimbabwe
CI	Côte d'Ivoire	KP	Democratic People's Republic of Korea	PL	Poland		
CM	Cameroon	KR	Republic of Korea	PT	Portugal		
CN	China	KZ	Kazakstan	RO	Romania		
CU	Cuba	LC	Saint Lucia	RU	Russian Federation		
CZ	Czech Republic	LI	Liechtenstein	SD	Sudan		
DE	Germany	LK	Sri Lanka	SE	Sweden		
DK	Denmark	LR	Liberia	SG	Singapore		
EE	Estonia						

## PIPERIDINE AND PYRROLIDINE DERIVATIVES COMPRISING A NITRIC OXIDE DONOR FOR TREATING STRESS

The present invention relates to compounds capable of acting both as sources of nitric oxide (NO-donors) and as scavengers of superoxide ion ( $O_2^-$ ) (superoxide dismutase (SOD)-mimetic).

- 5 Many disease states, including diabetes mellitus and various cardiovascular diseases, are associated with oxidative stress and endothelial dysfunction. In particular, endothelial dysfunction is the hallmark of the pathophysiological process (atherosclerosis) leading to a spectrum of clinically related diseases of the cardiovascular system (e.g. from stable angina pectoris to myocardial infarction (MI) and congestive heart failure), as well as  
10 being the primary event in pathologies relating to other body systems involving superoxide and/or other reactive oxygen species (ROS).

- For over a century, nitroglycerin (GTN) has been the drug of choice for the treatment of various types of myocardial ischemia (angina), including myocardial infarction, and a mainstay in the treatment of other heart diseases with and without ischemic etiology  
15 (congestive heart failure, isolated systolic and resistant hypertension). Because of its pathogenic nature (chronicity with acute exacerbation), prophylactic and acute treatments are necessary to prevent complications with potentially fatal outcomes (>25% death for acute MI).

- However, the phenomenon of tolerance to the anti-anginal effects of GTN and to all other  
20 existing organic nitrates is of a special clinical significance. In particular, early development of tolerance to the drug is by far the most serious drawback of nitrate therapy, especially during acute myocardial infarction.

- Evidence has been provided to support an involvement of the superoxide anion in the mechanism/s underlying nitrate tolerance and cross-tolerance (Munzel *et al.*, J. Clin.  
25 Invest. 95, 187-194 (1995)). According to this report, increased levels of superoxide anion were found to accompany tolerance development to GTN in vascular tissue after *in vivo* administration of the drug. Treatment with superoxide dismutase (SOD) significantly enhanced maximal relaxation of control and tolerant vascular tissue to GTN and other exogenous and endogenous vasodilators. This can be explained on the basis of an  
30 enhancing effect of superoxide on the induction of tolerance (pseudo-tolerance). It is

believed that if the normally tightly controlled balance between nitric oxide (NO) and superoxide ( $O_2^-$ ) in the vascular wall is disturbed, elevated levels of superoxide anion prevail, inactivating NO and furthermore generating toxic peroxynitrite. The protective effect of superoxide dismutase against nitrate tolerance has been demonstrated *in vitro* (Jia *et al.*, J. Pharmacol. Exp. Ther., 267,371-378 (1993) and Kowaluk *et al.*, J. Pharmacol. Exp. Ther., 255, 109-144 (1990)). However, being an enzyme, SOD is practically cell impermeable and cannot therefore be used therapeutically. There remains therefore a need for a nitrate-based therapy which does not suffer from the problem of nitrate tolerance.

- 10 According to the present invention there is provided a chemical compound comprising a nitric oxide (NO) donor and a superoxide ( $O_2^-$ ) scavenger.

The nitric oxide donor may comprise any group capable of acting as a source of nitric oxide (NO). Preferably, the nitric oxide donor is an  $-ONO_2$  group. The superoxide  
15 scavenger may comprise any group capable of acting as a scavenger of superoxide ( $O_2^-$ ). Preferably, the superoxide scavenger is a nitroxide free radical ( $N \rightarrow O \cdot$ ) group.

The compounds of the present invention may comprise one or more NO donors and one or more superoxide scavengers.


- 20 The compounds of the present invention not only provide a source of nitric oxide but in acting as an antioxidant scavenger of superoxide anion give rise to both a direct benefit derived from removal of injurious superoxide anion and a benefit in protecting both ambient and endogenous and liberated exogenous NO from inactivation by superoxide anion.
- 25 Without prejudice to the scope of the present invention, it is believed that oxidative damage is mediated by intracellular redox-active metal reactions catalyzed by highly reactive oxygen species (i.e. hydroxyl radicals). The generation of such reactive oxygen products depends on the availability of their common precursor; the superoxide anion. Mitochondria, microsomes and other various enzyme systems are known to produce  
30 superoxide anion that reacts with nitric oxide at or near diffusion controlled rates to form the powerful oxidant peroxynitrite. At pH 7.4, peroxynitrite protonates to form peroxynitrous acid (pKa 6.6) which decays homolytically to form hydroxyl and nitrogen

dioxide radicals in addition to a host of other ions. The extent to which these later reactive ions and radicals can cause cellular damage and death depends on the rate of formation of their peroxynitrite precursor. Under control (non-diseased) conditions, where the levels of NO are found in equilibrium between rates of NO-synthesis and degradation, the rate of formation of this peroxynitrite precursor is thought to depend solely on the levels of the superoxide anion. This is particularly important in cases involving "below-normal" levels of "biologically active" NO, such as in diseases for which therapeutic intervention with exogenous NO-donors is clinically indicated. Consequently, the extra- and intra-cellular activity of the enzyme SOD must have a cardinal role in maintaining cellular survival, tissue integrity and adequately balanced physiological function.

Since superoxide anion is an available and continuously-formed by-product generated through normal metabolic processes, and since its elimination is mediated either by dismutation by the enzyme SOD or via its reaction with NO to form the potentially hazardous peroxynitrite, it is now believed that the ultimate means by which a modification and/or treatment of 'pathological processes' involving imbalanced ratio of NO to superoxide is by an intervention with therapeutic agents capable of simultaneously and favourably affecting both components; the NO and  $O_2^-$ .

By virtue of the NO donor and superoxide scavenging activities being physically linked in the same molecule, the compounds of the present invention ensure that an increase in the level of NO is accompanied by reduced levels of superoxide thereby avoiding high levels of peroxynitrite and oxidant metabolites thereof. Preferred compounds according to the present invention are of the formula:-

Preferred compounds according to the present invention are of the formula:-



wherein  $R^1$  may be the same or different and are independently selected from hydrogen, alkoyl, alkoxy, carboxy, hydroxy, amino, amido, cyano, nitro, thio, sulphonyl, sulphoxide, alkyl groups and groups comprising an NO-donor, provided that at least one  $R^1$  is a group comprising an NO-donor group;

5  $R^2$  may the same or different and are independently selected from alkyl groups;

$n$  is an integer 1, 2 or 3;

or a salt thereof.

The groups  $R^1$  may be the same or different and are independently selected from hydrogen,  
10 alkoyl, alkoxy, carboxy, hydroxy, amino, amido, cyano, nitro, thio, sulphonyl, sulphoxide, alkyl groups and groups comprising an NO-donor group, provided that at least one  $R^1$  is a group comprising an NO-donor.  $R^1$  groups which do not comprise an NO-donor group are preferably hydrogen or alkyl groups. The or each  $R^1$  group comprising an NO-donor group may comprise one or more NO-donor groups. Preferably, the or each NO-donor  
15 group is an  $-ONO_2$  group.

The or each  $R^1$  group comprising an NO-donor group may comprise an NO-donor group alone or may comprise an NO-donor group linked via a  $C_1$  to  $C_{20}$  alkylene chain optionally comprising one or more heteroatoms. The alkylene chain may be branched or unbranched, cyclic or acyclic, saturated or unsaturated, where cyclic the alkylene chain is preferably  $C_3$   
20 to  $C_{12}$ , more preferably  $C_5$  to  $C_{10}$ , more preferably  $C_5$  to  $C_7$ . Where acyclic, the alkylene chain is preferably  $C_1$  to  $C_{16}$ , more preferably  $C_1$  to  $C_6$ . The alkylene chain may be unsubstituted or substituted as defined hereinbelow in respect of alkyl groups. The alkylene chain may comprise one or more heteroatoms, for example nitrogen, oxygen or sulphur atoms which may interrupt the alkylene chain or may link the alkylene chain to the  
25 NO-donor group or to the rest of the molecule (such that the  $R^1$  group comprising the NO-donor group is linked to the rest of the molecule via a heteroatom, such as an oxygen (e.g. ether linkage), nitrogen (e.g. amino or amido linkage) or sulphur (e.g. thioether linkage)).

Preferred  $R^1$  groups comprising NO-donors comprise groups of the formula:-



30 where X is absent or is O, NH or S; and

Y is a  $C_{1-20}$  alkylene chain

Preferably, X is O, NH or S.

In a preferred embodiment, at least one R<sup>1</sup> is a polar or ionisable group such as carboxyl or amino, which improves the solubility of the compound.

The groups R<sup>2</sup> may be the same or different and are selected from alkyl groups.

- 5 Preferably, the groups R<sup>2</sup> are each methyl groups. In an alternative preferred embodiment, one or more of the groups R<sup>2</sup> is a lipophilic group, such as a substituted or unsubstituted C<sub>1</sub> to C<sub>8</sub> alkyl group, capable of assisting in transport of the compound across the blood-brain membrane.

n may be 1, 2 or 3. Preferably n is 1 or 2, More preferably n is 2.

- 10 As used here reference to alkyl groups means a branched or unbranched, cyclic or acyclic, saturated or unsaturated (e.g. alkenyl or alkynyl) hydrocarbyl radical. Where cyclic, the alkyl group is preferably C<sub>3</sub> to C<sub>12</sub>, more preferably C<sub>5</sub> to C<sub>10</sub>, more preferably C<sub>5</sub> to C<sub>7</sub>. Where acyclic, the alkyl group is preferably C<sub>1</sub> to C<sub>16</sub>, more preferably C<sub>1</sub> to C<sub>6</sub>, more preferably methyl. Reference in the present specification to an alkoxy group means an
- 15 alkyl-O- group. Reference to alkoyl group means an alkyl-CO- group.

- The alkyl groups may be substituted or unsubstituted, preferably unsubstituted. Where substituted, there will generally be 1 to 3 substituents present, preferably 1 substituent. Substituents may include halogen atoms and halomethyl groups such as CF<sub>3</sub> and CCl<sub>3</sub>; oxygen containing groups such as oxo, hydroxy, carboxy, carboxyalkyl, alkoxy, alkoxy,
- 20 alkoyl, alkoyloxy, aryloxy, aryloyl and aryloyloxy; nitrogen containing groups such as amino, amido, alkylamino, dialkylamino, cyano, azide, nitrate and nitro; sulphur containing groups such as thiol, alkylthiol, sulphonyl and sulphoxide; heterocyclic groups containing one or more, preferably one, heteroatom, such as thienyl, furanyl, pyrrolyl, imidazolyl, pyrazolyl, thiazolyl, isothiazolyl, oxazolyl, pyrrolidinyl, pyrrolinyl,
- 25 imidazolidinyl, imidazolinyl, pyrazolidinyl, tetrahydrofuranyl, pyranal, pyronal, pyridyl, pyrazinyl, pyridazinyl, benzofuranyl, isobenzofuryl, indolyl, oxyindolyl, isoindolyl, indazolyl, indolinyl, 7-azaindolyl, isoindazolyl, benzopyranal, coumarinyl, isocoumarinyl, quinolyl, isoquinolyl, naphthridinyl, cinnolinyl, quinazolinyl, pyridopyridyl, benzoxazinyl, quinoxadinyl, chromenyl, chromanyl, isochromanyl and carbolinyl; alkyl groups, which
- 30 may themselves be substituted; and aryl groups, which may themselves be substituted,

such as phenyl and substituted phenyl. Alkyl includes substituted and unsubstituted benzyl.

Reference to amino includes substituted or unsubstituted amino.

Reference in the present specification to halogen means a fluorine, chlorine, bromine or iodine radical, preferably fluorine or chlorine radical.

The present invention extends to dimers and higher multimers of the compounds of the present invention; for example dimers of compounds of the present invention linked via R<sup>1</sup> groups (e.g. via an alkylene chain therein).


Particularly preferred compounds according to the present invention comprise:-

- 10        4-Nitrato-2,2,6,6-tetramethylpiperidinyloxy, free radical (TEMPO-4-mononitrate)
- 3,4-Dinitrato-2,2,6,6-Tetramethylpiperidinyloxy, free radical (TEMPO-3,4-dinitrate)
- 3,4,5-Trinitrato-2,2,6,6-Tetramethylpiperidinyloxy, free radical (TEMPO-3,4,5-trinitrate)
- 15        4-(2,3-Dinitrato-Prop-1-oxy)-2,2,6,6-Tetramethyl-piperidinyloxy, free radical (4-(2,3-dinitrato-prop-1-oxy) TEMPO)
- 1,3-di (4-Oxy-TEMPO)-2-Nitrato-Propane
- 1,4-di (4-Oxy-TEMPO)-2,3-Dinitrato-Butane
- 3-Nitrato-4-carboxy-2,2,6,6-tetramethylpiperidinyloxy, free radical (TEMPO-4-
- 20        carboxyl-3-nitrate)
- 4-Nitrato-3-carbamoyl-2,2,5,5-tetramethyl-3-pyrrolidin-1-yloxy, free radical (PROXYL-3-carbamoyl-4-nitrate)


The present invention further extends to methods of synthesising the compounds of the present invention. The compounds of the present invention may be synthesised according to the following generalised reaction schemes. It will be appreciated that the reaction schemes are merely illustrative of generally applicable procedures which may be modified as appropriate to produce the compounds of the present invention. In the following reaction schemes the 2,2,6,6-tetra substitution present in, for example TEMPO compounds is, for simplicity, not shown.




## Reaction Scheme 1



## Reaction Scheme 2




## Reaction Scheme 3




5


## Reaction Scheme 4




## Reaction Scheme 5




## Reaction Scheme 6



## Reaction Scheme 7



## Reaction Scheme 8



According to a further aspect of the present invention there is provided a compound  
 5 according to the present invention for use in a method of treatment.

The compounds of the present invention may be employed in the treatment of any  
 condition associated with endothelial dysfunction or oxidative stress including diabetes  
 mellitus, cardiovascular diseases (such as ischaemic heart disease, angina pectoris,  
 10 myocardial infarction, congestive heart failure, atherosclerosis, hypertension and

arrhythmia), asthma, trauma, shock (hypovolumic, neurogenic or septic), neurotoxicity, neurodegenerative and neurological disorders (including Alzheimer and Parkinson's diseases, amyotrophic lateral sclerosis, multiple sclerosis, convulsive (seizure) disorders, AIDS-dementia and disorders which involve processes of learning and memory), disorders  
5 of gastric secretions, relaxation and peristalsis of the intestinal tract (including sphincters), drug and disease-induced nephropathies, pathological (premature) and physiological uterine contractions, cellular defense impairment, endothelial dysfunction-induced diseases and insulin-resistance in diabetes, pregnancy-induced hypertension, chemotaxis and phagocytic impairment in immunological disorders, cerebrovascular diseases, aggregation  
10 disorders, fertility and reproductive disorders (e.g. penile erection and treatment of male impotence).

According to a further aspect of the present invention there is provided use of a compound according to the present invention for use in the manufacture of a medicament for treating a condition associated with oxidative stress or endothelial dysfunction, preferably diabetes  
15 mellitus or cardiovascular disease.

According to a further aspect of the present invention there is provided a method of treating a disease associated with oxidative stress or endothelial dysfunction (such as diabetes mellitus or cardiovascular disease) comprising administering to a patient in need  
20 of such treatment an effective dose of a compound of the present invention.

According to a further aspect of the present invention there is provided a pharmaceutical composition comprising a compound of the present invention in combination with a pharmaceutically acceptable excipient.  
25

Compounds of the present invention may be administered in a form suitable for oral use, for example a tablet, capsule, aqueous or oily solution, suspension or emulsion; for topical use including transmucosal and transdermal use, for example a cream, ointment, gel, aqueous or oil solution or suspension, salve, patch, plaster or as a component of a lubricant  
30 for a condom; for nasal use, for an example a snuff, nasal spray or nasal drops; for vaginal or rectal use, for example a suppository; for administration by inhalation, for example a finely divided powder or a liquid aerosol; for sub-lingual or buccal use, for example a

tablet or capsule; or for parenteral use (including intravenous, subcutaneous, intramuscular, intravascular or infusion), for example a sterile aqueous or oil solution or suspension, or incorporated in a biodegradable polymer. In general the above compositions may be prepared in a conventional manner using convention excipients, using standard techniques well known to those skilled in the art of pharmacy. Preferably, the compound is administered orally or topically.

For oral administration, the compounds of the invention will generally be provided in the form of tablets or capsules or as an aqueous solution or suspension.

Tablets for oral use may include the active ingredient mixed with pharmaceutically acceptable excipients such as inert diluents, disintegrating agents, binding agents, lubricating agents, sweetening agents, flavouring agents, colouring agents and preservatives. Suitable inert diluents include sodium and calcium carbonate, sodium and calcium phosphate, and lactose, while corn starch and alginic acid are suitable disintegrating agents. Binding agents may include starch and gelatin, while the lubricating agent, if present, will generally be magnesium stearate, stearic acid or talc. If desired, the tablets may be coated with a material such as glyceryl monostearate or glyceryl distearate, to delay absorption in the gastrointestinal tract.

Capsules for oral use include hard gelatin capsules in which the active ingredient is mixed with a solid diluent, and soft gelatin capsules wherein the active ingredient is mixed with water or an oil such as peanut oil, liquid paraffin or olive oil.

For intramuscular, intraperitoneal, subcutaneous and intravenous use, the compounds of the invention will generally be provided in sterile aqueous solutions or suspensions, buffered to an appropriate pH and isotonicity. Suitable aqueous vehicles include Ringer's solution and isotonic sodium chloride. Aqueous suspensions according to the invention may include suspending agents such as cellulose derivatives, sodium alginate, polyvinylpyrrolidone and gum tragacanth, and a wetting agent such as lecithin. Suitable preservatives for aqueous suspensions include ethyl and n-propyl p-hydroxybenzoate. The compounds of the invention may also be provided in a biodegradable polymer, for example for use in conjunction with stents in angioplasty (e.g. adsorbed on a stent or applied directly to the site of the procedure for slow release of the active agent).

It will be appreciated that the dosage levels used may vary over quite a wide range depending upon the compound used, the severity of the symptoms exhibited by the patient and the patient's body weight. Without limitation to the present invention, typical dosages for example for the treatment of angina may be of the order of 1 to 100 mg, preferably 5 to 40 mg, given two or three times daily or 1 to 200 mg, preferably 20 to 50 mg, in sustained release formulations given once or twice daily. Typical dosages for example for acute myocardial infarction may be of the order of 0.1 to 10 mg, preferably 1 to 2 mg, sublingually; 0.5 to 50 mg, preferably 5 to 10 mg, orally; or 1 to 100 micrograms, preferably 10 to 20 micrograms, per minute intravenously.

10

The invention will now be described with reference to the figures in which:

Figure 1 illustrates inhibition by TEMPO-4-mononitrate of reduction of ferricytochrome C by a xanthine oxidase/hypoxanthine superoxide anion generating system *in vitro*. Values are mean  $\pm$  s.e.m.

15

Figure 2 illustrates relaxation response curves of control RARs to GTN and NO-TEMPO;

Figure 3 illustrates relaxation response curves of control RARs to SNAP (n=8) and NO-TEMPO (n=11);

20

Figure 4 illustrates relaxation response curves to GTN of control and GTN-tolerant RARs;

Figure 5 illustrates relaxation response curves to NO-TEMPO of control (n=11) and GTN tolerant (n=7) RARs;

25

Figure 6 illustrates relaxation response curves of NO-TEMPO-pretreated RARs (0.44 mM of NO-TEMPO) to GTN and NO-TEMPO;

30

Figures 7 illustrates relaxation response curves to NO-TEMPO before and after pretreatment of RARs with 0.44 mM of NO-TEMPO; and



Figure 8 illustrates relaxation response curves of RARs (n=8) to GTN before and after pretreatment with 0.44 mM of NO-TEMPO.

It will be appreciated that the invention is described by way of example only, and that  
5 modifications of detail may be made without departing from the scope of the present invention.

## EXPERIMENTAL

### Synthesis of Compounds

4-Nitrato-2,2,6,6-tetramethylpiperidinyloxy, free radical (TEMPO-4-mononitrate) –  
10 (Reaction Scheme 1)

The title compound was prepared by nitration of commercially available 4-hydroxy-TEMPO. 4-Hydroxy-TEMPO (Aldrich Chemical Co.) (20 mmol) was added portionwise to a cooled (0-5°C) mixture of fuming nitric acid (3 ml) and concentrated sulphuric acid (3 ml). After addition was complete, the mixture was brought to room temperature and  
15 stirred vigorously for a further 15 minutes. The mixture was added continuously and dropwise to a cooled (5°C) mixture of diethylether:acetonitrile:water (150ml:50ml:25ml) with vigorous stirring. Sodium chloride (5g) was added to facilitate separation of the organic layer, which was then evaporated to dryness under reduced pressure. The residue was dissolved in diethyl ether (50ml) and washed twice with ice-water (20ml) and once  
20 with 2% aq. potassium carbonate (20ml) before being dried (MgSO<sub>4</sub>) and evaporated to dryness.

Alternatively, nitration of 4-hydroxy-TEMPO (and nitration of all other hydroxy precursors described by this invention) can be easily achieved by direct exposure of the compound to the gaseous nitrating agent dinitrogen tetroxide (N<sub>2</sub>O<sub>4</sub>). Here, N<sub>2</sub>O<sub>4</sub> (1.25  
25 equivalents) was introduced to the desired weight into a tarred, precooled (-20°C) round-bottom flask containing 50 ml of dry tetrahydrofurane-hexane mixture (1:1). 4-Hydroxy-TEMPO (1 equivalent) dissolved in dry tetrahydrofurane (25 ml, -20°C) was added dropwise into the nitrating solution with stirring. The reaction temperature was maintained below -10°C during the entire addition period, after which it was left to rise to  
30 room temperature within 1 hr. Nitrogen gas was bubbled into the reaction mixture until no more red gas is seen to exit in the upper part of the flask. The organic solvents were evaporated to near dryness and the residue dissolved in methyl tert-butyl ether (100 ml),

washed once with water (50 ml) and twice with 50 ml ice-cold 2% sodium bicarbonate solution. The ether was separated, dried ( $\text{MgSO}_4$ ) and evaporated to dryness.

The red residue was purified by column chromatography using silica gel (60) and eluted with diethyl ether: petroleum ether (20:80) to furnish the title compound in 90-95% yield.

- 5 The identity of the product was confirmed by NMR and ESR spectroscopy and by TLC analysis by reaction with diphenylamine, which after heating to  $80^\circ\text{C}$  for 1 minute, gives a deep green colour typical of nitrated nitroxides.

- Alternatively, the title compound was prepared by dissolving 3.44 g (20 mmol) of 4-hydroxy-TEMPO in 50 ml of dichloromethane. The mixture was cooled on ice bath and 6  
10 ml of thionyl bromide in 25 ml of dichloromethane was added dropwise during 30 min. After completion the reaction was stirred for an additional 3 hours during which it reached room temperature. The solvent was washed successively with water (75 ml) and 10% sodium carbonate solution (75 ml), dried ( $\text{MgSO}_4$ ) and evaporated to dryness. The residue was chromatographed on silica gel and eluted with petroleum ether: dichloromethane  
15 (80:20) to furnish 4.71g (94%) of pure 4-bromo-TEMPO. The product was dissolved in 50 ml of acetonitrile containing 4.25g (25 mmol) of argentum nitrate. The reaction mixture was heated at  $60^\circ\text{C}$  for 4 hours. The precipitate was removed by filtration and washed with 30 ml of cold acetonitrile. The combined filtrate was removed to dryness under reduced pressure and separated by chromatography as described above to furnish  
20 4.2g (87%) of the title compound.

The following compounds were prepared using similar procedures and in accordance with the Reaction Schemes set out above:-

3,4-Dinitrato-2,2,6,6-Tetramethylpiperidinyloxy, free radical (TEMPO-3,4-dinitrate)

3,4,5-Trinitrato-2,2,6,6-Tetramethylpiperidinyloxy, free radical (TEMPO-3,4,5-trinitrate)

- 25 4-(2,3-Dinitrato-Prop-1-oxy)-2,2,6,6-Tetramethyl-piperidinyloxy, free radical (4-(2,3-dinitrato-prop-1-oxy) TEMPO)

1,3-di (4-Oxy-TEMPO)-2-Nitrato-Propane

1,4-di (4-Oxy-TEMPO)-2,3-Dinitrato-Butane

4-Nitrato-3-carboxyl-2,2,6,6-tetramethylpiperidinyloxy, free radical (TEMPO-3-carboxyl-4-nitrate)

3,4-Dinitrato-2,2,6,6-tetramethylpiperidinyloxy, free radial (TEMPO-3,4-dinitrate) – Reaction Scheme 2)

- 5 To 4.26 g (25 mmol) of 4-oxo-2,2,6,6-tetramethyl-1-piperidinyloxy, free radical (4-oxo-TEMPO, Aldrich Chemical Co.) dissolved in 50 ml of carbon tetrachloride (CCl<sub>4</sub>) there was added portion wise 4.895g (27.5 mmol) of dried, fine powder of N-bromosuccinimide over 25 min with stirring. The reaction was left overnight and filtered. The precipitate was washed with 20 ml of CCl<sub>4</sub> and the combined filtrate evaporated to dryness under
- 10 reduced pressure. The red oil residue (which solidifies to a waxy product upon standing for one day) was chromatographed on silica gel and eluted with chloroform:hexane (60:40) to furnish 5.42g (87%) of 3-bromo-4-oxo-TEMPO. The product was dissolved in 50 ml of dry diethyl ether and added in one portion to ice-cold 25 ml of 1.0M solution of lithium aluminum hydride in diethyl ether. After stirring for 30 min on ice bath, 25 ml of
- 15 methanol was added dropwise to destroy excess hydride.

The solvent was filtered and evaporated to dryness. The crude residue was dissolved in dichloromethane (50 ml) and treated for 5 hours with thionyl bromide (6 ml) at room temperature. The reaction mixture was washed twice with equal volumes of water and twice with 5% sodium carbonate solution and organic phase separated and dried on

20 magnesium sulfate. After removing the solvent under reduced pressure, the desired dibromo derivative was isolated by column chromatography (silica gel 60) after elution with petroleum ether. The red oily product was dissolved in 50 ml of acetonitrile containing 30 mmol argentic nitrate and nitration and separation of the desired dinitrated derivative performed as described above for the mononitrated TEMPO.

25 3,4,5-Trinitrato-2,2,6,6-tetramethylpiperidinyloxy, free radial (TEMPO-3,4,5-trinitrate) – (Reaction Scheme 3)

- To 4.26 g (25 mmol) of 4-oxo-2,2,6,6-tetramethyl-1-piperidinyloxy, free radical (4-oxo-TEMPO, Aldrich Chemical Co.) dissolved in 150 ml of carbon tetrachloride (CCl<sub>4</sub>) there was added portion wise 98g (55 mmol) of dried, fine powder of N-bromosuccinimide over
- 30 25 min with stirring. The reaction was left overnight and filtered. The precipitate was

washed with 25 ml of  $\text{CCl}_4$  and the combined filtrate evaporated to dryness under reduced pressure. The red oil residue was chromatographed on silica gel and eluted with chloroform:hexane (30:70) to furnish 6.75g (82%) of 3,5-dibromo-4-oxo-TEMPO. The product was dissolved in 100 ml of dry diethyl ether and added in one portion to ice-cold  
5 50 ml of 1.0M solution of lithium aluminum hydride in diethyl ether. After stirring for 20 min on ice bath, 25 ml of methanol was added dropwise to destroy excess hydride.

The solvent was filtered and evaporated to dryness. The crude residue was dissolved in dichloromethane (50 ml) and treated for 5 hours with thionyl bromide (6 ml) at room temperature. The reaction mixture was washed twice with equal volumes of water and  
10 twice with 5% sodium carbonate solution and organic phase separated and dried on magnesium sulfate. After removing the solvent under reduced pressure, the desired tribromo derivative was isolated by column chromatography (silica gel 60) after elution with heptane. The red oily product was dissolved in 150 ml of acetonitrile containing 0.1 M argentic nitrate and nitration and separation of the desired dinitrated derivative  
15 performed as described above for the mono and dinitrated TEMPO.

4-(2,3-Dinitrato-prop-1-oxy)-2,2,6,6-tetramethylpiperidinyloxy, free radical (4-[2,3-dinitrato-prop-1-oxy]-TEMPO) – (Reaction Scheme 4)

4.3g of 4-hydroxy-TEMPO (25 mmol) was dissolved in 50 of dry tetrahydrofuran (THF) and cooled on ice bath. 0.66g (27.5 mmol) of metal sodium was added in one portion and  
20 the reaction mixture stirred vigorously for 40 min. 25 ml of THF containing 3.76g (27.5 mmol) of epibromohydrin was added dropwise with stirring at room temperature for one hour. The reaction mixture was evaporated to dryness and residue treated with 20% sodium hydroxide solution for 3 hours at 55°C. After cooling, the reaction mixture was extracted 3 times with 50 ml each of ethyl acetate. The organic layer was separated and  
25 the combined extracts dried and evaporated to dryness. The viscous oily residue was added to a cooled (0°C) mixture of fuming nitric acid and sulfuric acid (3.7 ml each) and stirred for 30 min. The reaction mixture was poured in 1 ml portions into a 300 ml of cold water: acetonitrile:diethyl ether mixture (10:20:70) and stirred for 10 min while nitrogen gas was bubbled into the stirred solution. The organic phase was separated, washed with  
30 water and 5% sodium carbonate solution, dried over magnesium sulfate and evaporated to dryness. The reddish oily residue was separated over silica gel and eluted with chloroform

to yield 5.1g (61% based on 4-hydroxy-TEMPO) of the desired product 4-(2,3-Dinitratoprop-1-oxy)-2,2,6,6-tetramethylpiperidinyloxy, free radical (4-[2,3-dinitrato-prop-1-oxy]-TEMPO).

1,3-Di-(4-oxy-TEMPO)-2-nitratopropane – (Reaction Scheme 5)

- 5 8.6g (50 mmol) of 4-hydroxy-TEMPO were dissolved in 80 ml of dry tetrahydrofuran (THF) and cooled on ice bath. 1.44g (60 mmol) of metal sodium was added in one portion and the reaction mixture stirred vigorously for 40 min. 25 ml of THF containing 5.4g (25 mmol) of dibromoacetone was added dropwise with stirring at room temperature for one hour. The reaction mixture was cooled on ice-water bath and 30 ml of 1.0 M solution of
- 10 lithium aluminum hydride in diethyl ether was added in one portion. After stirring for 20 min on ice bath, 25 ml of methanol was added dropwise to destroy excess hydride. The solvent was filtered and evaporated to dryness. The viscous oily residue was added to a cooled (0°C) mixture of fuming nitric acid and sulfuric acid (3.7 ml each) and stirred for 30 min. The reaction mixture was poured in 1 ml portions into a 300 ml of cold water:
- 15 acetonitrile:diethyl ether mixture (10:20:70) and stirred for 10 min while nitrogen gas was bubbled into the stirred solution. The organic phase was separated, washed with water and 5% sodium carbonate solution, dried over magnesium sulfate and evaporated to dryness. The reddish oily residue was separated over silica gel and eluted with dichloromethane:diethyl ether (80:20) to yield 6.45g (57% based on 4-hydroxy-TEMPO)
- 20 of the desired product 1,3-Di-(4-oxy-TEMPO)-2-nitratopropane.

1,4-Di-(4-oxo-TEMPO)-2,3-dinitratobutane – (Reaction Scheme 6)

- 8.6g (50 mmol) of 4-hydroxy-TEMPO were dissolved in 80 ml of dry tetrahydrofuran (THF) and cooled on ice bath. 1.44g (60 mmol) of metal sodium was added in one portion and the reaction mixture stirred vigorously for 40 min. 25 ml of THF containing 2.15g (25
- 25 mmol) of (+)-1,3-butadiene diepoxide was added dropwise with stirring at room temperature for five hours. The reaction mixture was filtered and evaporated to dryness. The viscous oily residue was added to a cooled (0°C) mixture of fuming nitric acid and sulfuric acid (5.8 ml each) and stirred for 30 min. The reaction mixture was poured in 1 ml portions into a 300 ml of cold water:acetonitrile:diethyl ether mixture (10:20:70) and
- 30 stirred for 10 min while nitrogen gas was bubbled into the stirred solution. The organic phase was separated, washed with water and 5% sodium carbonate solution, dried over

magnesium sulfate and evaporated to dryness. The reddish oily residue was separated over silica gel and eluted with dichloromethane:diethyl ether (60:40) to yield 5.59g (43% based on 4-hydroxy-TEMPO) of the desired product 1,4-Di-(4-oxo-TEMPO)-2,3-dinitratobutane.

5 4-Nitrato-3-carbamoyl-2,2,5,5-tetramethyl-3-pyrrolidin-1-yloxy, free radical (PROXYL-3-carbamoyl-4-nitrate) – (Reaction Scheme 7)

3.6 g (20 mmol) of 3-carbamoyl-2,2,5,5-tetramethyl-3-pyrrolidin-1-yloxy, free radical commercially available from Aldrich Chemical Co. was added portion wise to 6 ml of cool concentrated hydrobromic acid solution containing 50 mg of 1,1'-azobis  
10 (cyclohexanecarbonitrile) and stirred overnight. The resulting solution was diluted with 14 ml of ice cold water and extracted 5 times each of 50 ml of ether. The combined ether extracts was washed twice with water and twice with 30 ml each of 5% sodium carbonate solution. The organic solvent was dried (sodium sulfate) and evaporated to dryness. The resulting crude 4-bromo-3-carboxy derivative was dissolved in 50 ml of acetonitrile, 6 g of  
15 argentum nitrate were added and the solution refluxed for 2 hrs. After cooling to room temperature, the inorganic salts were removed by filtration and the organic solvent removed. The residue was triturated with a mixture of hexane-ether solution (1:1) and the solvent removed. The residue was then separated by flash chromatography (dichloromethane:ethyl acetate 4:1) to give the pure title compound.

20 3-Nitroatomethyl-2,2,5,5-tetramethylpyrrolidinyloxy, free radical (3-nitratomethyl-PROXYL) – (Reaction Scheme 8)

To 4.26 g (25 mmol) of 4-oxo-2,2,6,6-tetramethyl-1-piperidinyloxy, free radical (4-oxo-TEMPO) dissolved in 50 ml of carbon tetrachloride (CCl<sub>4</sub>) there was added portion wise 4.895g (27.5 mmol) of dried, fine powder of N-bromosuccinimide over 25 min with  
25 stirring. The reaction was left overnight and filtered. The precipitate was washed with 20 ml of CCl<sub>4</sub> and the combined filtrate evaporated to dryness under reduced pressure. The red oil residue (which solidifies to a waxy product upon standing for one day) was chromatographed on silica gel and eluted with chloroform:hexane (60:40) to furnish 5.42g (87%) of 3-bromo-4-oxo-TEMPO. The product was dissolved in 20 ml of methanol and  
30 added dropwise to 30 ml of ice-cold, freshly prepared solution of sodium methoxide (60 mmol). After addition is complete, the reaction mixture is stirred at room temperature for

5 hours at the end of which the reaction is brought to reflux for 30 min. After cooling, the solvent was filtered and evaporated to dryness under reduced pressure. The residue was dissolved in 50 ml of dry diethyl ether and added dropwise to 30 ml of 1.0 M solution of lithium aluminum hydride in diethyl ether. After stirring for 20 min on ice bath, 25 ml of methanol was added dropwise to destroy excess hydride. The solvent was filtered and evaporated to dryness. The viscous oily residue was added to a cooled (0°C) mixture of fuming nitric acid and sulfuric acid (3.7 ml each) and stirred for 30 min. The reaction mixture was poured in 1 ml portions into a 300 ml of cold water:acetonitrile:diethyl ether mixture (10:20:70) and stirred for 10 min while nitrogen gas is bubbled into the stirred solution. The organic phase was separated, washed with water and 5% sodium carbonate solution, dried over magnesium sulfate and evaporated to dryness. The yellow-orange oily residue was separated over silica gel and eluted with dichloromethane:hexane (80:20) to yield the title compound 3-nitratomethyl-2,2,5,5-tetramethylpyrrolidinyloxy, free radical (3-nitratomethyl-PROXYL) in 63% yield.

## 15 Biological Testing

### *Assessment of superoxide scavenging activity in vitro*

The superoxide scavenging activity of TEMPO-4-mononitrate (0.003-3 mM) and reference compound superoxide dismutase (SOD, 200 U/ml), were determined using a photometric microassay *in vitro* (Laight *et al.*, Environ. J. Toxicol. Pharmacol., 3, 65-68, 1997) developed from the assay of McCord & Fridovich (J. Biol. Chem., 244, 6059-55, 1969). The assay mixture consisted of (final concentration): 50 µl ferricytochrome c (100 µM); 10 µl xanthine oxidase (20 mU/ml); 20 µl hypoxanthine (100 µM); and 20 µl sample dissolved in isotonic phosphate (10 mM)-buffered saline (PBS, pH 7.4) to make a total volume of 100 µl in a 96-well plate. The reaction was conducted at room temperature and initiated by the addition of hypoxanthine. The increase in optical density (OD) at 500 nm was measured over a 3 min period of 30 s intervals and initial reaction rates determined at least in triplicate.

There was a linear relationship between the initial reaction rate and the concentration of xanthine oxidase (5-20 mU/ml) ( $r=0.9982$ ,  $P<0.002$ ,  $n=4$ ). Blank controls lacking either enzyme or substrate showed no activity. Xanthine oxidase at 20 mU/ml, which provided an initial reaction rate of  $28.3\pm1.7$  mOD/min ( $n=4$ ), was adopted for subsequent inhibition

studies (see McCord & Fridovich, 1969). The initial reaction rate was depressed by SOD (200 U/ml) by  $95.3 \pm 1.1\%$  ( $n=4$ ,  $P<0.01$ ) and by TEMPO-4-mononitrate (see Figure 1). TEMPO-4-mononitrate exhibited a  $pIC_{50}$  value of  $2.89 \pm 0.03$  ( $n=5$ ,  $p<0.001$ ).

## 5 *Vasorelaxation and Tolerance-Inducing Properties*

**Materials:** Male Sprague-Dawley rats (250-300 g) were purchased from the Animal Care Facility of the Hebrew University and used in the rat aortic rings (RARs) relaxation studies in vitro and the blood pressure monitoring and cGMP studies in vivo.

10

**In vitro vasorelaxation:** Thoracic aortae were removed following anesthesia with intraperitoneal injection of ketamine and xylazine (50 and 10 mg/kg, respectively). The paraadventetial tissue surrounding the vessel was carefully removed. Aortae were cut into rings of 4-5 mm and mounted onto the tissue path. The path buffer (Krebs-bicarbonate) was constantly gassed with carbogen and maintained at 37°C. The rings were preloaded under 2 g tension and equilibrated for 90 min with buffer changed every 15 min. After stabilization, the rings were contracted with epinephrine (1  $\mu$ M). Commulative Concentration-Response Curves (CCRC) were constructed for NO-TEMPO, glyceryl trinitrate (GTN) and S-nitroso-N-acetylpenicillamine (SNAP). Figures 2 and 3 represent the vaso-relaxant effect of NO-TEMPO as compared to the conventional NO-donors GTN and SNAP. These figures demonstrate the superiority of NO-TEMPO to both of these NO-donors.

**In vitro induction of GTN tolerance:** Aortic rings were treated as for the control studies except that rings were exposed to 0.44 mM GTN for 1 hr. At the end of the tolerance induction period, rings were washed every 15 min for the following hour. Attempted induction of tolerance to NO-TEMPO was performed under the same conditions as for GTN with rings exposed to 0.44 mM solution of NO-TEMPO. CCRC were constructed for NO-TEMPO and GTN. Figure 4 shows the vaso-relaxant effect of GTN on rings before and after exposure to 0.44 mM of the drug and it clearly demonstrates the development of GTN tolerance under these conditions. This tolerance is also crossed to NO-TEMPO as is obvious from Figure 5, where a significant difference between the effects of NO-TEMPO on rings before and after pre-treatment with GTN



exists. However, when the vaso-relaxant activity of NO-TEMPO and GTN were examined using NO-TEMPO-pre-treated RARs, no significant differences between the potencies of these drugs were obtained between control RARs (Figure 2) and NO-TEMPO-pretreated RARs (Figure 6). This observation demonstrates that, under the condition applied, tolerance to NO-TEMPO does not develop. This conclusion is further supported by separately evaluating the vaso-relaxant effect of each drug on control and NO-TEMPO-pre-treated RARs. Thus, as is obvious from Figure 7, no significant difference was observed in the vaso-relaxant potency of NO-TEMPO between control and NO-TEMPO-pre-treated RARs. Similarly, no significant difference exists in the potency of GTN between control and NO-TEMPO-pre-treated RARs (Figure 8). These results demonstrate that, whereas GTN induces tolerance both to itself and to NO-TEMPO, NO-TEMPO does not induce tolerance neither to itself nor to GTN.

#### **In vivo vasorelaxation and induction of GTN tolerance**

Results obtained from evaluating the hypotensive effects of NO-TEMPO in vivo also demonstrated the superiority of this drug to both GTN and SNAP. Moreover, vascular cGMP measurements following in vivo administration of NO-TEMPO showed its superior activity as compared to GTN in control rats and the lack of tolerance induction to its effect in NO-TEMPO pre-treated rats.

20

In the in vivo experiment, rats were anesthetized with an intraperitoneal injection of a combination of ketamine and xylazine (50 and 10 mg per kg, respectively). A catheter was placed in the right external jugular vein and introduced to the level of right atrium. A second arterial catheter was placed in the left carotid artery and introduced to the level of the ascending aorta. The tip of arterial catheter was connected to a pressure transducer which is connected to another electrical transducer connected to a computerized Experimetria system. Blood-pressure (mean arterial pressure=MAP) was recorded before (basal) and after drug administration. NO-TEMPO was injected through the venous catheter and induced a significant drop in MAP which lasts for 5 to 10 minutes. Values for basal MAP were  $130 \pm 15$  before and  $60 \pm 10$  mm Hg following a 1 mg injection of NO-TEMPO. Unlike with GTN and SNAP, where attenuation to their effect on MAP develops, the hypotensive effect of NO-TEMPO on MAP was consistent and was

repeatable following successive administration of NO-TEMPO, which indicated the lack of tolerance development to the drug.

#### *Effect on cGMP and Tolerance to Organic Nitrates*

5

Administration of TEMPO-4-mononitrate resulted in a significant increase in cGMP content of vascular tissue.. Although it bears only one nitrate group, the effect of TEMPO-4-mononitrate on vascular cGMP compared well with that of GTN, despite the latter containing 3 such groups when both drugs are administered intravenously in equimolar  
10 doses to control rats.

Experiments were performed in anaesthetized rats as above. Following i.v. administration of NO-TEMPO (0.1, 0.2, 0.5 mg etc.,) the thorax was opened and the aorta removed immediately (within thirty seconds from the administration). After standard processing  
15 procedures, cGMP content in the vascular tissue was measured by Radioimmunoassay (RIA) using commercially available kits (i.e., Kit 500 TRK from Amersham). Typical basal values of cGMP in aortic tissue were  $46 \pm 10$  versus  $197 \pm 18$  pmole/g tissue obtained following administration of 1 mg of NO-TEMPO (a 4-5-fold increase in vascular cGMP).

20 When given subcutaneously (30 mg/kg t.i.d for three consecutive days), NO-TEMPO does not induce tolerance either to itself or to GTN, whereas GTN administered in the same route does induce tolerance to itself and to NO-TEMPO.

#### Conclusion

25


It is clear that the compounds of the present invention exhibit both superoxide scavenging and vasodilator activity, fulfilling the combined roles of organic nitrate and antioxidant. Moreover, they act as potent superoxide anion scavengers at concentrations which liberate therapeutic amounts of NO. In addition, the compounds of the present invention do not  
30 induce tolerance to themselves or conventional organic nitrates. The compounds of the present invention therefore have exceptional therapeutic utility, particularly in conditions with adverse responsiveness to organic nitrates.

## CLAIMS-

1. A chemical compound comprising a nitric oxide (NO) donor and a superoxide ion ( $O_2^-$ ) scavenger.

5

2. A chemical compound according to claim 1 of the formula:



wherein R<sup>1</sup> may be the same or different and are independently selected from hydrogen, alkoyl, alkoxy, carboxy, hydroxy, amino, amido, cyano, nitro, thio, sulphonyl, sulphoxide alkyl groups and groups comprising an NO-donor, provided that at least one R<sup>1</sup> is a group comprising an NO-donor;

R<sup>2</sup> may be the same or different and are independently selected from alkyl groups;

n is an integer 1, 2 or 3;

or a salt thereof.

3. A compound according to claim 1 wherein the nitric oxide donor is an -ONO<sub>2</sub> group.

20

4. A compound according to any one of claims 1 to 3 wherein the superoxide ion scavenger is a nitroxide (N→O) group.

5. A chemical compound according to any one of claims 2 to 4 wherein R<sup>2</sup> are methyl groups.

25


6. A compound according to any one of claims 2 to 5 wherein n is 2.
7. A compound according to any one of claims 2 to 5 wherein at least one R<sup>1</sup> is a group of the formula:  

$$-X-Y-ONO_2$$


where X is absent or is O, NH or S; and  
Y is a C<sub>1-20</sub> alkylene chain
8. A compound selected from the following compounds:  
4-Nitrato-2,2,6,6-tetramethylpiperidinyloxy, free radical (TEMPO-4-mononitrate)  
3,4-Dinitrato-2,2,6,6-Tetramethylpiperidinyloxy, free radical (TEMPO-3,4-dinitrate)  
3,4,5-Trinitrato-2,2,6,6-Tetramethylpiperidinyloxy, free radical (TEMPO-3,4,5-trinitrate)  
4-(2,3-Dinitrato-Prop-1-oxy)-2,2,6,6-Tetramethyl-piperidinyloxy, free radical (4-(2,3-dinitrato-prop-1-oxy) TEMPO)  
1,3-di (4-Oxy-TEMPO)-2-Nitrato-Propane  
1,4-di (4-Oxy-TEMPO)-2,3-Dinitrato-Butane  
4-Nitrato-3-carboxyl-2,2,6,6-tetramethylpiperidinyloxy, free radical (PROXYL-3-carboxyl-4-nitrate)  
4-Nitrato-3-carbamoyl-2,2,5,5-tetramethyl-3-pyrrolidin-1-yloxy, free radical (PROXYL-3-carbamoyl-4-nitrate)
9. A compound according to any one of claims 1 to 8 for use in a method of treatment.
10. Use of a compound according to any one of claims 1 to 8 for use in the manufacture of a medicament for treating a condition associated with oxidative stress or endothelial dysfunction, preferably diabetes mellitus or cardiovascular disease.

11. A method of treating a disease associated with oxidative stress or endothelial dysfunction comprising administering to a patient in need of such treatment an effective dose of a compound of any one of claims 1 to 8.
- 5 12. A pharmaceutical composition comprising a compound of any one of claims 1 to 8 in combination with a pharmaceutically acceptable excipient.


1/8

**FIG. 1**

2 / 8


**FIG. 2**

3/8


**FIG. 3**




4/8

**FIG. 4**


5/8

**FIG. 5**


6 / 8

**FIG. 6**

7/8

**FIG. 7**

8/8

**FIG. 8**

# INTERNATIONAL SEARCH REPORT

International Application No

PCT/GB 99/00231

## A. CLASSIFICATION OF SUBJECT MATTER

IPC 6 C07D211/46 C07D207/12 C07D207/08 A61K31/445 A61K31/40

According to International Patent Classification (IPC) or to both national classification and IPC

## B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC 6 C07D A61K

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

## C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	CHEMICAL ABSTRACTS, vol. 119, no. 25, 20 December 1993 Columbus, Ohio, US; abstract no. 262465, ROBAK J. ET AL.: "Nitric oxide donors as generators and scavengers of superoxide anions" XP002100912 see abstract & POL. J. PHARMACOL., vol. 45, no. 1, 1993, pages 51-58, ---	1-12
P, A	WO 98 42661 A (YISSUM RES DEV CO ;HAJ YEHA ABDULLAH (IL)) 1 October 1998 see claims -----	1-12

☐ Further documents are listed in the continuation of box C.

☒ Patent family members are listed in annex.

### \* Special categories of cited documents :

"A" document defining the general state of the art which is not considered to be of particular relevance

"E" earlier document but published on or after the international filing date

"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)

"O" document referring to an oral disclosure, use, exhibition or other means

"P" document published prior to the international filing date but later than the priority date claimed

"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.

"&" document member of the same patent family

Date of the actual completion of the international search

29 April 1999

Date of mailing of the international search report

18/05/1999

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2  
NL - 2280 HV Rijswijk  
Tel. (+31-70) 340-2040, Tx. 31 651 epo nl,  
Fax: (+31-70) 340-3016

Authorized officer

Chouly, J

## INTERNATIONAL SEARCH REPORT

International application No.

PCT/GB 99/ 00231

### Box I Observations where certain claims were found unsearchable (Continuation of Item 1 of first sheet)

This International Search Report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. ☒ Claims Nos.: claim 11  
because they relate to subject matter not required to be searched by this Authority, namely:  
Remark: Although claim 11  
is directed to a method of treatment of the human/animal  
body, the search has been carried out and based on the alleged  
effects of the compound/composition.
2. ☐ Claims Nos.:  
because they relate to parts of the International Application that do not comply with the prescribed requirements to such  
an extent that no meaningful International Search can be carried out, specifically:
3. ☐ Claims Nos.:  
because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

### Box II Observations where unity of invention is lacking (Continuation of Item 2 of first sheet)

This International Searching Authority found multiple inventions in this international application, as follows:

1. ☐ As all required additional search fees were timely paid by the applicant, this International Search Report covers all  
searchable claims.
2. ☐ As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment  
of any additional fee.
3. ☐ As only some of the required additional search fees were timely paid by the applicant, this International Search Report  
covers only those claims for which fees were paid, specifically claims Nos.:
4. ☐ No required additional search fees were timely paid by the applicant. Consequently, this International Search Report is  
restricted to the invention first mentioned in the claims; it is covered by claims Nos.:

Remark on Protest

- ☐ The additional search fees were accompanied by the applicant's protest.
- ☐ No protest accompanied the payment of additional search fees.

### Information on patent family members

PCT/GB 99/00231

Form PCT/SA/210 (patent family annex) (July 1992)